Abeona Therapeutics

Epidermolysis bullosa patient has foot bandaged
#Abeona Therapeutics #Epidermolysis bullosa #FDA #Gene therapy

Gene therapy for severe skin disease secures historic approval

The US Food and Drug Administration (FDA) has approved Abeona Therapeutics’ Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel.  Zevaskyn is an autologous cell-based gene therapy for the treatment of wounds in adult and paediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).  “Today’s approval of Zevaskyn represents a… Read More

#News #Regulatory #Trending News